The responsibilities and procedures applicable to the quality control unit are not in writing.
Inspection Record
Diversified Pharmacy Inc dba University Compounding Pharmacy — FDA 483 Findings
Inspectors Sarah M. Napier · Emily J. OrbanThe inspectors who signed the published document.Inspector lookup
View the regulator's official source The source document is always the basis for judgement.
Findings
Each batch of drug product purporting to be sterile and pyrogen-free is not laboratory tested to determine conformance to such requirements.
Aseptic processing areas are deficient regarding systems for maintaining any equipment used to control the aseptic conditions.
Aseptic processing areas are deficient regarding the system for monitoring environmental conditions.
Procedures designed to prevent microbiological contamination of drug products purporting to be sterile are not established.
Container closure systems do not provide adequate protection against foreseeable external factors in storage and use that can cause deterioration or contamination of the drug product .
There is no written testing program designed to assess the stability characteristics of drug products.
The operations relating to the processing ofpenicillin are not performed in facilities separate from those used for other drug products for human use.
About this record
Extracted automatically from the document US FDA published on 2024-01-17. The source is available at the link above.
This is a record of that moment. Inspection findings are usually followed by the company's response and corrective action, but this page does not know how that turned out. Do not read it as the current state; check the regulator's official announcements for the latest status.
Translation and classification are automated and may differ in nuance from the source.
